Graphite Bio Inc (GRPH)

$2.48

+0.11

(+4.64%)▲

Market is closed - opens 7 PM, 02 Oct 2023

Insights on Graphite Bio Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 82.6% return, outperforming this stock by 104.4%

Performance

  • $2.36
    $2.49
    $2.48
    downward going graph

    4.79%

    Downside

    Day's Volatility :5.18%

    Upside

    0.4%

    downward going graph
  • $1.59
    $3.69
    $2.48
    downward going graph

    35.89%

    Downside

    52 Weeks Volatility :56.91%

    Upside

    32.79%

    downward going graph

Returns

PeriodGraphite Bio IncSector (Health Care)Index (Russel 2000)
3 Months
-4.62%
-3.0%
0.0%
6 Months
2.9%
0.5%
0.0%
1 Year
-25.3%
6.3%
6.3%
3 Years
-89.87%
22.1%
17.3%

Highlights

Market Capitalization
130.5M
Book Value
$3.87
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.15
Wall Street Target Price
3.6
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-19.06%
Return On Equity TTM
-45.69%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-94.9M
Diluted Eps TTM
-2.15
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.65
EPS Estimate Next Year
-0.7
EPS Estimate Current Quarter
-0.31
EPS Estimate Next Quarter
-0.22

Analyst Recommendation

Hold
    0
    0%Buy
    63%Hold
    36%Sell
Based on 11 Wall street analysts offering stock ratings for Graphite Bio Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
7
7
9
Sell
4
4
4

Analyst Forecast

What analysts predicted

Upside of 45.16%

Current $2.48
Target $3.60

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Graphite Bio Inc
Graphite Bio Inc
9.25%
2.9%
-25.3%
-89.87%
-89.87%
Moderna, Inc.
Moderna, Inc.
-11.43%
-29.94%
-12.65%
45.99%
455.32%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.44%
1.41%
19.47%
47.01%
108.75%
Novo Nordisk A/s
Novo Nordisk A/s
-3.29%
15.05%
82.56%
161.96%
290.64%
Seagen, Inc.
Seagen, Inc.
2.56%
4.47%
55.05%
8.41%
161.4%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.86%
11.4%
20.1%
27.79%
81.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Graphite Bio Inc
Graphite Bio Inc
0.45
NA
NA
-1.65
-0.46
-0.19
0.0
3.87
Moderna, Inc.
Moderna, Inc.
34.94
34.94
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.08
22.08
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
43.05
43.05
2.03
1.64
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.67
26.67
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Graphite Bio Inc
Graphite Bio Inc
Hold
$130.5M
-89.87%
0.45
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.2B
455.32%
34.94
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.6B
108.75%
22.08
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$412.6B
290.64%
43.05
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$39.8B
161.4%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$89.7B
81.52%
26.67
35.4%

Institutional Holdings

  • EcoR1 Capital, LLC

    14.73%

  • Samsara BioCapital, LLC

    14.59%

  • TANG CAPITAL MANAGEMENT LLC

    3.60%

  • BlackRock Inc

    2.95%

  • Prosight Management, LP

    2.93%

  • Vanguard Group Inc

    2.38%

Company Information

graphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company’s platform harnesses the natural cellular process of homology directed repair (hdr) and targeted dna integration to precisely repair genetic defects at their source. graphite bio is leveraging its differentiated platform to advance a portfolio of transformative genetic treatments with potential for saving and dramatically improving patients’ lives

Organization
Graphite Bio Inc
Employees
120
CEO
Dr. Joshua Lehrer-Graiwer FACC, M.D.
Industry
Electronics Distributors

Discover More

FAQs